Lesions of the Inferior Olive in Cases of Autoimmune GFAP Astrocytopathy: A Case Series Report
By
Haruka Kuwashige
Atsuhiko Sugiyama
Shinji Aoyama
Hideo Handa
Mitsuyoshi Tamura
Hiroki Masuda
Yuki Nakagawa
Masahiro Namiki
Hajime Yokota
Hiroki Mukai
Akio Kimura
Takayoshi Shimohata
Masahiro Mori
January 31, 2026
Clinical Scorecard: Lesions of the Inferior Olive in Cases of Autoimmune GFAP Astrocytopathy: A Case Series Report
At a Glance
Category Detail
Condition Autoimmune GFAP Astrocytopathy Key Mechanisms Presence of IgG autoantibodies against GFAP and involvement of GFAP-specific cytotoxic T cells. Target Population Patients with autoimmune GFAP astrocytopathy, potentially triggered by neoplasms or viral infections. Care Setting Neurology and inpatient hospital care.
Key Highlights
Characterized by IgG autoantibodies against GFAP. Clinical presentation includes meningoencephalitis and myelitis. MRI findings include T2 hyperintensities in the ION and spinal cord. Treatment includes high-dose intravenous immunoglobulin and corticosteroids. Clinical improvement observed with appropriate immunotherapy. Guideline-Based Recommendations
Diagnosis
MRI findings of T2 hyperintensities in the brain and spinal cord. CSF analysis showing elevated white blood cells and protein levels. Management
Initiate treatment with intravenous methylprednisolone and intravenous immunoglobulin. Consider oral corticosteroids for ongoing management. Monitoring & Follow-up
Regular follow-up MRI to assess lesion resolution. Monitor neurological status and CSF parameters. Risks
Potential for respiratory failure and neurological deterioration. Risk of complications from immunotherapy. Patient & Prescribing Data
Adults with autoimmune GFAP astrocytopathy presenting with neurological symptoms.
Combination therapy with IV immunoglobulin and corticosteroids can lead to significant recovery.
Clinical Best Practices
Early recognition of symptoms and prompt MRI evaluation. Multidisciplinary approach for management including neurology and rehabilitation. Consideration of underlying triggers such as neoplasms or infections. Related Resources & Content
